Veradermics (MANE) Non-Current Assets (2025 - 2026)
Veradermics (MANE) posted Non-Current Assets of $287000.0 for Q1 2026, up 129.6% on a QoQ basis from $125000.0 in Q4 2025.
Veradermics (MANE) Non-Current Assets (2025 - 2026) Analysis & Trends
Veradermics' Non-Current Assets history runs 2 years deep, the most recent figure standing at $287000.0 for Q1 2026.
- Quarterly Non-Current Assets changed N/A year-over-year to $287000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $287000.0 (changed N/A YoY) and the FY2025 annual result came in at $125000.0, changed N/A from the prior year.
- Non-Current Assets was $287000.0 for Q1 2026 at Veradermics, up from $125000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $287000.0 in Q1 2026 and bottomed at $125000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Veradermics | 2.63 Bn | 2.63 Bn | - | 287,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 287,000.00 |
| Dec 31, 2025 | 125,000.00 |